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Serotonin has been implicated in the pathogenesis of pul-monary arterial hypertension (PAH)1–3 and has been 
recognized as a potent naturally occurring pulmonary vaso-
constrictor4 and smooth muscle cell mitogen.2 Serotonin pro-
motes pulmonary artery (PA) remodeling and proliferation of 
human PA smooth muscle cells (hPASMCs) via the 5-HT1B 
receptor (5-HT1BR) and the serotonin transporter (SERT).5–8 
Serotonin can also cause constriction of human and rodent 
PAs via the 5-HT1BR.4,9
Reactive oxygen species (ROS), produced primarily by the 
NADPH oxidase (Nox) family of enzymes in the vasculature, 
induce oxidative stress and play a critical role in oxidative 
damage to proteins, lipids, and DNA.10 Altered redox signal-
ing and increased ROS bioavailability have been implicated 
in chronic diseases, including PAH.11,12 Excessive amounts of 
ROS in PAs can oxidize and inactivate signaling molecules, 
such as protein tyrosine phosphatases (PTPs), or can drive 
irreversible protein modification through addition of carbonyl 
groups on protein side chains, a marker for oxidative stress.12,13
Intracellular ROS levels are regulated by the balance 
between ROS-generating enzymes, such as Noxs, and anti-
oxidant enzymes that include superoxide dismutases, catalase, 
and the peroxiredoxin systems,14 which are regulated by a key 
transcription factor Nrf-2 (nuclear factor [erythroid-derived 
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2]-like 2). Nrf-2 activators attenuate experimental pulmonary 
hypertension (PH).15 Increased expression of Nox isoforms 1 
and 4 in PAs has been demonstrated in experimental models of 
PH and in PASMCs from PAH patients.12 Cellular Src-related 
kinase (c-Src) is the predominant nonreceptor tyrosine kinase 
in the vasculature, which is required for regulation of Nox 
activity,16 and this may be dysregulated in PAs of PAH patients 
and experimental PH.17
Serotonin-induced ROS has been implicated in the prolif-
erative response of proximal bovine and murine PASMCs.18,19 
However, it is unclear whether serotonin influences ROS in 
hPASMC and is the focus of our study.
Although studies have shown that serotonin promotes PA 
remodeling mainly through SERT and 5-HT1BR,4,7,20 the role of 
Nox isoforms in serotonin-dependent ROS production, anti-
oxidant regulation, and redox-sensitive processes downstream 
of ROS production has yet to be investigated. It is important 
to investigate this in the distal hPASMCs that contribute to the 
pathophysiology of PAH. For the first time, we investigate the 
role of serotonin in Nox-derived ROS in hPASMCs, specifi-
cally, Nox1-derived ROS in serotonin-induced Nrf-2 dysfunc-
tion, protein carbonylation, and oxidation of antioxidant and 
signaling molecules, peroxiredoxin, and PTPs.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Serotonin Increases ROS Production
Basal ROS production was higher in human pulmonary artery 
smooth muscle cells from PAH subjects (PAH-hPASMCs) 
compared with hPASMCs. In hPASMCs, serotonin increased 
.O2− production at 1, 4, and 24 hours of stimulation, whereas 
in PAH-hPASMCs serotonin increased .O2− generation more 
rapidly at 30 minutes and 1 hour (Figure 1A). In control 
hPASMCs, serotonin-induced .O2− generation was blocked by 
5-HT1BR antagonist, SB224289, but not a SERT antagonist 
(citalopram) or a 5-HT1D/2AR inhibitor (ketanserin). In PAH-
hPASMCs, both the 5-HT1BR and the SERT mediate .O2− gen-
eration as SB224289 and citalopram blocked the effects of 
serotonin (Figure 1B). No effects were observed with sero-
tonin receptor antagonists alone (data not shown).
The Nox1 inhibitor ML171, and the radical scavenger 
tempol, inhibited serotonin-induced ·O2− formation in con-
trol and PAH-hPASMCs (Figure 1C). To control for non-
specific effects of ML171, we examined ROS production in 
mouse PASMCs (mPASMCs) derived from wild-type (WT) 
and Nox1−/− mice. Serotonin-induced ROS production was 
observed in WT mPASMCs but absent in Nox1−/− mPASMCs 
at 30 minutes’ stimulation (Figure 1D).
c-Src may be involved in transactivation and phosphoryla-
tion of subunits required for Nox assembly21 and is a proximal 
regulator of vascular Nox activation.16 Exposure of PAH-
hPASMCs to a Src kinase inhibitor, PP2, inhibited serotonin-
induced ROS in PAH-hPASMCs while having no effect in 
control hPASMCs (Figure 2A).
Hydrogen peroxide (H2O2) is a common substrate for the 
peroxidation reaction of peroxiredoxins.22 Basal intracellu-
lar H2O2 levels, assessed by Amplex red, were increased in 
PAH-hPASMCs versus controls. Serotonin caused H2O2 pro-
duction at 5 and 30 minutes in control hPASMCs, whereas 
H2O2 production in PAH-hPASMCs was more sustained from 
30 minutes to 4 hours (Figure IA in the online-only Data 
Supplement). In control hPASMCs, serotonin reduced cata-
lase activity to similar levels observed in the PAH-hPASMCs, 
whereas in PAH-hPASMCs, serotonin further reduced activity 
of catalase after 5 minutes (Figure IB in the online-only Data 
Supplement). In line with accumulation of H2O2, there was 
a reduction in basal catalase activity in PAH versus control 
hPASMCs (Figure IB in the online-only Data Supplement). 
In addition, catalase activity was reduced by serotonin treat-
ment (30 minutes to 2 hours) in control hPASMCs. In PAH-
hPASMCs, the already lowered basal catalase activity was 
further attenuated by serotonin more rapidly than in the control 
cells, at 5 minutes’ stimulation (Figure IB in the online-only 
Data Supplement). In support, glutathione mRNA levels were 
significantly attenuated in PAH-hPASMCs versus control 
hPASMCs (Figure IC in the online-only Data Supplement).
Regulation of Nox Isoforms by 
Serotonin in hPASMCs
Basal gene expression of Nox1 was increased in PAH-
hPASMCs compared with controls (Figure 2B). Serotonin 
increased Nox1 mRNA expression in control hPASMCs to 
levels observed in PAH-hPASMCs. In PAH-hPASMCs, sero-
tonin also increased mRNA expression of Nox1 (Figure 2B).
Regulation of Nrf-2 and Antioxidant 
Systems by Serotonin
Serotonin increased Nrf-2 activity in control hPASMCs; 
yet, in PAH-hPASMCs, a statistically significant increase 
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in Nrf-2 activity was not observed with serotonin treatment 
(Figure 2C). Peroxiredoxin is hyperoxidized and inactivated 
through sulfonylation. Basal levels of hyperoxidized perox-
iredoxin in PAH-hPASMCs were elevated compared with 
control hPASMCs. Serotonin increased protein expression of 
hyperoxidized peroxiredoxin in control hPASMCs at 1-hour 
stimulation, and these effects were blocked by 5-HT1BR antag-
onist, SB224289 (Figure 2D).
Serotonin Influences Redox Signaling in hPASMCs
Serotonin increased irreversible PTP oxidation exclusively in 
PAH-hPASMCs, inhibited by 5-HT1BR inhibitor, SB224289, 
and the Nox1 inhibitor, ML171 (Figure 3A; Figure IIA in the 
online-only Data Supplement). Consistent with this, serotonin 
increased irreversible oxidation of PTPs in WT mPASMCs but 
had no effect in Nox1−/− mPASMCs (Figure 3B; Figure IIB in 
the online-only Data Supplement). Carbonylation of proteins 
is a hallmark of oxidative stress. Basal protein carbonylation 
was increased in PAH-hPASMCs versus control hPASMCs, 
with no significant effects of serotonin (Figure 3C). There 
were increased levels of carbonylation in WT, but not Nox1−/−, 
mPASMCs on serotonin treatment (Figure 3D). Basal Rho-
kinase (ROCK) activity was increased in PAH-hPASMCs. 
Serotonin increased activity in PAH-hPASMCs, an effect that 
was inhibited by SB224289 and ML171 (Figure III in the 
online-only Data Supplement).
Serotonin-Induced Proliferation Involves Nox
Serotonin-induced proliferation was increased in PAH-
hPASMCs versus control hPASMCs (Figure 4A). In line with 
ROS production, these effects were attenuated by the 5-HT1BR 
inhibitor and the Nox1 inhibitor in hPASMCs, with additional 
inhibitory effects of SERT inhibitor, citalopram, in PAH-
hPASMCs (Figure 4A). Consistent with this, proliferation was 
reduced in Nox1−/− mouse-derived mPASMCs compared with 
WT mPASMCs when treated with serotonin (Figure 4B).
Serotonin-Induced Alterations in Markers 
of Fibrosis and Extracellular Matrix 
Remodeling Involve Nox1-Derived ROS
Extracellular matrix remodeling is a key process involved in 
the pathobiology of PAH.23,24 Loss of balance between matrix 
Figure 1. Serotonin increases reactive oxygen species (ROS) production through Nox-dependent mechanisms. Time-dependent increase of 
ROS production by serotonin (1 µmol/L) in control human pulmonary artery smooth muscle cells (hPASMCs) and pulmonary arterial hyper-
tension (PAH)-hPASMCs assessed by lucigenin-enhanced chemiluminescence (A). hPASMCs and human pulmonary artery smooth muscle 
cells from PAH subjects (PAH-hPASMCs) were exposed to serotonin for the time of peak ROS production (1 h) previously shown in (A), in the 
presence or absence of inhibitors of Nox1 (ML171, 1 µmol/L) and superoxide dismutase mimetic Tempol (10 µmol/L; B). Serotonin-induced 
ROS production in wild-type (WT) and Nox1−/− mouse pulmonary artery smooth muscle cells (mPASMCs; C). ROS production by serotonin 
(1 µmol/L) in control hPASMCs and PAH-hPASMCs at 1 h stimulation, in the presence or absence of 5-HT
1B
R antagonist, SB224289, SERT 
inhibitor, citalopram (Cit), or 5-HT
2A/1D
R antagonist (D). Data are expressed as relative light units (RLU)/µg protein, expressed as percent-
age of vehicle control conditions. Results are mean±SEM of 5 experiments, in triplicate. *P<0.05 vs vehicle control hPASMC or vehicle WT 
mPASMCs; †P<0.05 vs treated control hPASMC; ‡P<0.05 vs vehicle PAH-hPASMCs; §P<0.05, §§P<0.01 vs treated PAH-hPASMCs deter-
mined by ANOVA with Tukey post hoc test. Ket indicates ketanserin; ML, ML171; SB, SB224289; Ser, serotonin; Tem, Tempol; and V, vehicle.
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metalloproteinases (MMPs) and TIMPs (tissue inhibitor of 
matrix metalloproteinases) initiates extracellular matrix and 
vascular remodeling. Basal MMP2 mRNA was elevated in 
PAH-hPASMCs and further increased by serotonin; these 
effects were 5-HT1BR- and Nox1-dependent, through the use 
of pharmacological inhibitors, SB224289 and ML171, respec-
tively (Figure 4C). Basal MMP9 transcript was elevated in PAH-
hPASMCs, and serotonin further stimulated MMP9 in both 
control and PAH-hPASMCs, effects attenuated in the presence 
of 5-HT1BR antagonist, SB224289, and Nox1 inhibitor, ML171 
(Figure 4D). Serotonin had no effect on secretion of platelet-
derived growth factor subunit B (homodimer) from hPASMCs 
(Figure IVA in the online-only Data Supplement). Protein expres-
sion of platelet-derived growth factor receptor beta (PDGFR-β) 
was increased under basal conditions in PAH-hPASMCs ver-
sus control hPASMCs, whereas in control hPASMCs serotonin 
increased expression of PDGFR-β where this increase was 
attenuated in the presence of 5-HT1BR antagonist SB224289 
(Figure IVB in the online-only Data Supplement).
5-HT1BR and Nox1 Staining in 
Human Lung Tissue Sections
In human lung sections from control subjects, 5-HT1BR stain-
ing was absent. In contrast, 5-HT1BR staining was evident in 
Figure 2. Effect of serotonin on Nrf-2 activation and oxidation of peroxiredoxin. Serotonin-induced reactive oxygen species (ROS) 
production in the presence or absence of Src kinase inhibitor, PP2 (10 µmol/L) in control human pulmonary artery smooth muscle cell 
(hPASMC) and pulmonary arterial hypertension (PAH)-hPASMCs. Data are expressed as relative light units (RLU)/µg protein, expressed 
as percentage of vehicle control conditions (A). Transcript levels of Nox1 (B) in response to serotonin. Nuclear translocation of Nrf-2 by 
serotonin at 5 min to 4 h was assessed as an indicator of Nrf-2 activity. Data are expressed as RLU/µg protein expressed as percentage 
of vehicle control conditions (C). Effects of serotonin (1–2 h) in the presence or absence of the 5-HT
1B
R antagonist, SB224289, on protein 
expression of hyperoxidized peroxiredoxin, hyperoxidized peroxiredoxin (PRDX-SO
3
H) in hPASMCs (D). Results are mean±SEM of 3 to 
6 experiments. Graph represents mRNA expression relative to GAPDH. *P<0.05, **P<0.01 vs vehicle control hPASMC or wild-type (WT) 
vehicle mouse pulmonary artery smooth muscle cells (mPASMCs); †P<0.05 vs serotonin 1 h control hPASMCs; vehicle human pulmonary 
artery smooth muscle cells from PAH subjects (PAH-hPASMCs; Nox1); ‡P<0.05, ‡‡ P<0.01 vs vehicle PAH-hPASMCs; §§P<0.01 vs sero-
tonin-treated PAH-hPASMCs determined by ANOVA with Tukey post hoc test. ns indicates not significant; SB, SB224289; Ser, serotonin; 
and V, vehicle.
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both the endothelium and the smooth muscle of pulmonary 
arteries in human lung sections from patients with PAH. Nox1 
staining was present in smooth muscle of pulmonary arteries 
of human lung sections derived from both controls and patients 
with PAH (Figure V in the online-only Data Supplement).
5-HT1BR Antagonism In Vivo Attenuates 
Development of PH in the SERT+ Mouse 
and Chronic Hypoxic Mouse
Female mice that overexpress the gene for human SERT 
demonstrate PH.6 Lungs from serotonin transporter over-
expressing (SERT+) mice demonstrated increased oxida-
tive stress.25 The 5-HT1BR antagonist, SB216641, reduced 
the increase in right ventricular systolic pressure (RVSP) 
in SERT+ mice (Figure 5A), and as shown before,6 SERT+ 
mice show no change in right ventricular hypertrophy (RVH; 
Figure 5B). PA remodeling was increased in SERT+ mice, 
and this was reduced by SB216641 (Figure 5C). There was 
no change in mean arterial pressure (Figure VIA in the 
online-only Data Supplement) or heart rate (Figure VIB in 
the online-only Data Supplement) by SB216641 in WT or 
SERT+ mice. In addition, oral administration of SB216641 
(15 mg/kg/d) protected against elevations in RVSP, RVH, and 
the development of pulmonary vascular lesions/remodeling 
in 8- to 10-week-old female C57BL/6J mice exposed to 15 
days chronic hypoxia. Age-matched female mice maintained 
under normoxic conditions were used as controls (Figure 
VII in the online-only Data Supplement). PA remodeling 
was also increased in hypoxic mice compared with their nor-
moxic counterparts, and this remodeling was ameliorated by 
SB216641 (Figure VIII in the online-only Data Supplement). 
No effects were observed in normoxic control mice treated 
with SB216641 (Figures VII and VIII in the online-only Data 
Supplement).
We investigated whether oxidative stress was regulated 
by serotonin (and the 5-HT1BR) in SERT+ mice by immuno-
histochemical analysis of 8-OHG (8-hydroxyguanosine), a 
fluorescent ROS probe, which specifically detects oxidative 
damage to nucleic acids. Female SERT+ mice had increased 
levels of 8-OHG compared with WT mice, and SB21664 
treatment reduced 8-OHG levels (Figure IX in the online-only 
Data Supplement). 8-OHG staining was observed in both the 
Figure 3. Effects of serotonin on oxidation of protein tyrosine phosphatases (PTPs) and global protein carbonylation. Irreversible oxi-
dation of PTPs using the oxPTP antibody, in response to serotonin in human pulmonary artery smooth muscle cells (hPASMCs) in the 
presence or absence of SB224289 or Nox1 inhibitor, ML171 (A). PTP oxidation in wild-type (WT) and Nox1−/− mouse pulmonary artery 
smooth muscle cells (mPASMCs) treated with serotonin (B). Total protein carbonylation in response to serotonin in hPASMCs (2 h; 
C) and in Nox1−/− mPASMCs (1 h; D). Results are representative of 3 to 5 experiments where protein expression is relative to β-actin. 
*P<0.05, **P<0.01, vs vehicle control hPASMCs or WT vehicle mPASMCs; †P<0.05 vs treated WT mPASMCs; ‡‡P<0.01 vs vehicle pul-
monary arterial hypertension (PAH)-hPASMCs; §P<0.05, §§P<0.01 vs serotonin-treated human pulmonary artery smooth muscle cells 
from PAH subjects (PAH-hPASMCs) determined by ANOVA with Tukey post hoc test. ML indicates ML171; SB, SB224289; Ser, sero-
tonin; and V, vehicle.
D
ow
nloaded from
 http://ahajournals.org by on May 13, 2019
1366  Arterioscler Thromb Vasc Biol  July 2017
cytoplasm and the nucleus, indicating increased RNA and 
DNA oxidation.
Discussion
Our novel findings demonstrate that in hPASMCs serotonin 
stimulates ROS through Nox, downregulates protective anti-
oxidant mechanisms, stimulates redox signaling and irre-
versible protein oxidation and carbonylation, and promotes 
molecular and cellular processes associated with extracel-
lular matrix remodeling and cell growth. These serotonin 
effects are amplified in hPASMCs from patients with PAH 
and involve c-Src–regulated Nox1 and 5-HT1BR and Nrf-2 
dysfunction (summarized in Figure X in the online-only Data 
Supplement). Using SERT+ mice, we confirm, in vivo, our 
cell-based findings.
The 5-HT1BR receptor is highly expressed in human 
PAs, with increased expression in PAH patients,4 and medi-
ates serotonin-induced vasoconstriction and PA remodeling. 
The 5-HT2AR mediates these effects systemically and so the 
5-HT1BR effects are pulmonary specific, making it a favor-
able target for PAH. Serotonin-dependent ROS production in 
hPASMCs was dependent on 5-HT1BR in control hPASMCs, 
whereas in PAH-hPASMCs this was mediated by both the 
SERT and the 5-HT1BR. Consistently, there is an increase in 
SERT expression in PAs and hPASMCs from PAH patients.26 
Female mice overexpressing SERT have a PH phenotype.6 
There is co-operation between SERT and 5-HT1BR in human 
and experimental PAH,5,20 and dual blockade of the 5-HT1BR 
and SERT is a plausible therapeutic approach.
Growing evidence implicates a role for Noxs, particu-
larly Nox1 and Nox4, in the pathogenesis of experimental 
and human PAH.12,27 In addition to the constitutive expression 
of Nox1 in a variety of tissues, Nox1 expression is increased 
after inflammation, growth factor stimulation, and hypoxia.28 
Nox1 also plays a critical role in physiological turnover of 
PASMCs by regulation of intracellular potassium.29
We observed that serotonin induces ROS production 
through Nox1 activation in hPASMCs. Although peak ROS 
levels induced by serotonin are similar between control 
and PAH-hPASMCs, we suggest that PAH-hPASMCs are 
already primed to ROS, as basal levels are increased in PAH-
hPASMCs versus control hPASMCs. We note that although 
Figure 4. Role of 5-HT
1B
R and Nox1 in serotonin-mediated cell proliferation and extracellular matrix remodeling. To test whether sero-
tonin regulates proliferation in a Nox/reactive oxygen species (ROS)-dependent manner, BrdU (5-Bromo-2′-deoxyuridine) incorporation 
was assessed in human pulmonary artery smooth muscle cells (hPASMCs; A) and wild-type (WT) and Nox1−/− mouse pulmonary artery 
smooth muscle cells (mPASMCs) in response to serotonin (B). Transcript expression of MMP2 (C) and MMP9 (D) after treatment with 
serotonin with or without SB224289 or ML171. Results are representative of 5 experiments per group where mRNA expression is normal-
ized to GAPDH. *P<0.05, **P<0.01, ***P<0.001 vs vehicle control hPASMCs or WT vehicle mPASMCs; †P<0.05, ††P<0.01 vs serotonin-
treated control hPASMCs; ‡P<0.05 vs vehicle pulmonary arterial hypertension (PAH)-hPASMCs or serotonin-treated mPASMCs; §P<0.05, 
§§P<0.01 vs serotonin-treated PAH-hPASMCs determined by ANOVA with Tukey post hoc test. Cit indicates citalopram; ML, ML171; 
MMP, matrix metalloproteinase; SB, SB224289; Ser, serotonin; and V, vehicle.
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ROS levels were sustained in control hPASMCs, they were 
quickly recovered in PAH-hPASMCs. Although glutathione 
transcript level is reduced in PAH versus control hPASMCs, 
there is no further impairment after serotonin stimulation. 
Similarly, although catalase activity is downregulated by sero-
tonin in control hPASMCs up to 2 hours, in PAH-hPASMCs, 
catalase activity recovers more rapidly than in control 
hPASMCs. Moreover, we found that this effect is mediated 
via c-Src because PP2, which inhibits Src family kinases, 
attenuated serotonin-induced Nox1 activation. c-Src plays an 
important role in activation of MAPKs associated with cell 
growth, apoptosis, and collagen deposition.30 Previous stud-
ies demonstrated that c-Src is both a redox-sensitive down-
stream target of Nox and an upstream signaling molecule for 
Nox activation31 and can increase protein abundance subunits 
and adaptor proteins required for regulation of Nox activity.16 
Importantly, PP2 reduced serotonin-stimulated ROS forma-
tion exclusively in PAH-hPASMCs, suggesting a role for 
c-Src in serotonin-mediated Nox activation in PAH.
High concentrations of ROS trigger the oxidation of PTPs, 
resulting in their loss of function as a phosphate acceptor.32 
In association with excessive ROS production by serotonin, 
we found an increase in irreversibly oxidized PTPs. Our find-
ings suggest that PTP inhibition may play a role in PAH and 
that serotonin-induced Nox1-derived ROS may be important 
in this process.
Other molecular processes that are redox-sensitive relate 
to total protein carbonyl content, an important index of whole 
cell protein oxidation.33 Accumulation of protein carbonyls 
has been observed in several human pathologies, including 
diseases of the lung.34 We found increased protein carbon-
ylation in basal conditions, in PAH-hPASMCs compared 
with control cells, along with increased carbonyl content in 
response to serotonin in WT mPASMCs, an effect that was 
absent in mPASMCs from Nox1−/− mice. This suggests a role 
for Nox1-derived ROS in the regulation of protein carbonyl-
ation in hPASMCs. It has been reported that an alternative 
strategy to antioxidant intervention is to detoxify oxidative-
derived carbonyl reaction products.35 Thus, strategies to regu-
late carbonyl content may have clinical value.
Peroxiredoxin is an antioxidant enzyme important in the 
degradation of H2O2, which can modulate various receptor 
signaling pathways and protects cells from oxidation-induced 
death. The active site cysteine (Cys) of peroxiredoxin is oxi-
dized to the sulfenic acid intermediate (Cys-SOH) when a 
peroxide is reduced. Yet, because Cys-SOH is unstable, it 
forms a disulfide with Cys-SH. However, under oxidative 
stress conditions, the sulfenic intermediate (Cys-SOH) can 
Figure 5. Hemodynamic assessment of pulmonary hypertension in female wild-type (WT) and serotonin transporter overexpressing 
(SERT+) mice treated with SB216641. Right ventricular systolic pressure (RVSP; A), right ventricular (RV) hypertrophy (B). Effects of 
SB216641 on percentage of pulmonary vascular remodeling in distal pulmonary arteries in female WT and SERT+ mice with representa-
tive images (right) of pulmonary arteries (Elastin Van Gieson stain; scale bars=50 µm; C). Results are mean±SEM, n=8 to 10 per group. 
***P<0.001 vs WT vehicle, †††P<0.001 vs SERT+ vehicle, determined by 2-way ANOVA with Tukey post hoc test. Data are mean±SEM. 
n=8 to 10 per group. **P<0.01 vs WT vehicle; †P<0.05 vs SERT+ vehicle, determined by 2-way ANOVA with Tukey post hoc test.
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be easily overoxidized to cysteine sulfinic or sulfonic (Cys-
SO2H/-SO3H) acids, referred to as hyperoxidation. H2O2 is a 
common substrate for the peroxidation reaction of peroxire-
doxins and also a well-known cause for their hyperoxidation.22 
In our study, serotonin caused excessive production of H2O2 in 
PAH-hPASMCs, as well as decreased activity of H2O2 reduc-
ing enzymes, catalase, and glutathione, in PAH-hPASMCs 
versus control hPASMCs. These effects were further reduced 
in serotonin-treated PAH-hPASMCs, indicative of increased 
production and accumulation of H2O2 in PAH, potentiated by 
serotonin. In control hPASMCs, serotonin stimulated ROS 
production and increased Nrf-2 activity, perhaps as a com-
pensatory mechanism to maintain redox balance. However, 
in PAH-hPASMCs, serotonin increased ROS production, yet 
did not induce activity of Nrf-2 as an antioxidant defense 
mechanism, suggesting overall ROS accumulation and oxida-
tive damage. Of clinical significance, Nrf-2 activators are in 
human trials for PAH and can attenuate experimental PH.15
To better understand the functional significance of sero-
tonin-induced oxidative stress, we studied effects on molec-
ular regulators of vascular contraction and proliferation, 
hallmarks of vascular remodeling in PAH. In human PAH, 
ROCK inhibitors cause modest reductions in pulmonary vas-
cular resistance.36 As such, ROCK has been implicated in both 
PA contraction and remodeling.37 Serotonin-induced PASMC 
proliferation, contraction, and migration involve ERK1/2 
MAPK and ROCK. Serotonin-mediated signaling of ROCK 
occurs through 5-HT1BR activation in a lung fibroblast cell 
line.8 Here, we show in hPASMCs that serotonin-mediated 
activation of ROCK is mediated via the 5-HT1BR and Nox1-
derived ROS. Serotonin stimulated cell proliferation, which 
was exaggerated in PAH-hPASMCs and dependent on the 
5-HT1BR and Nox1 because these effects were absent in 
the presence of inhibitors of this receptor and oxidase, and 
in Nox1−/− mice. Apoptosis is another key factor in vascular 
remodeling characteristic of PAH, as such, it has been previ-
ously shown that serotonin inhibits PASMC apoptosis through 
5-HT1BR or SERT.38 It would be interesting to understand the 
role of serotonin and the 5-HT1BR in other vascular cell com-
ponents, such as human PA endothelial cells, primary cultures 
of such cells are not readily available from control subjects 
and patients with PAH, and therefore are difficult to study in 
relation to the human disease.
Structural remodeling of pulmonary arteries through 
smooth muscle cell migration, proliferation, and oversecre-
tion of extracellular matrix are the most notable pathologi-
cal changes in PAH.39 The MMPs, particularly gelatinases 
MMP2 and MMP9, are involved in extracellular matrix turn-
over and hence, in smooth muscle cell migration and prolif-
eration. Of note, promoters of functionally related MMPs, 
such as MMP2/MMP9, are clearly distinct, pointing to dif-
ferent mechanisms of activation.40 As evidenced here and as 
shown previously, concomitant increments in both MMPs are 
not always observed. For example, in a rat model of pancre-
atitis-induced lung injury, MMP9 increased in lung tissue, 
whereas MMP2 remained unchanged.41 However, the promo-
tor for MMP2 does not harbor a TATA box, and expectedly, 
transcription from these promoters starts at multiple sites. 
Such that, expression of MMP2 is mainly determined by the 
ubiquitous Sp1 family of transcription factors, where expres-
sion of MMP2 in the main part is constitutive, with only mod-
est sensitivity to induction by growth factors or cytokines.42 
This is in line with our data showing that MMP2 transcript 
is induced by serotonin solely in PAH-hPASMCs, whereas 
MMP9 mRNA expression is sensitive to serotonin stimula-
tion in both control and PAH-hPASMCs. Vascular remodel-
ing in both experimental and human PAH has been shown to 
involve increased expression of profibrotic proteins. In the 
lung of PAH patients, accelerated turnover of the extracellu-
lar matrix because of increased MMP activity occurs.23 Loss 
of balance between MMPs and TIMPs initiates extracellular 
matrix and vascular remodeling and is involved in a variety 
of pathologies.43 Serotonin increased expression of the pro-
fibrotic signaling proteins MMP2 and MMP9 in hPASMCs. 
These effects were absent in hPASMCs pretreated with inhibi-
tors of the 5-HT1BR or Nox1, suggesting an important role for 
Nox1 in the profibrotic effects of serotonin.
The rationale for platelet-derived growth factor involve-
ment in the pathogenesis of PAH is strong, with increased 
expression of ligand and phosphorylated receptor in patient 
lung tissue.44 However, we did not observe any change in the 
platelet-derived growth factor subunit B (homodimer) levels 
in the spent culture medium from serotonin-stimulated control 
and PAH-hPASMCs. Because both serotonin and PDGFR-β 
have been associated with clinical and experimental PH, 
and patients with PA hypertension have enhanced activation 
of PDGFR-β in their lungs,44 we investigated whether there 
is a relationship between these molecules in  hPASMCs. 
Expression of PDGFR-β was increased under basal conditions 
in PAH-hPASMCs versus control hPASMCs, whereas in con-
trol hPASMCs, serotonin increased expression of PDGFR-β, 
where this increase was absent in the presence of 5-HT1BR 
antagonist SB224289. A previous study in bovine-derived 
PASMCs observed serotonin-stimulated production of ROS 
serving as an intermediate in the transactivation of PDGFR-β 
by serotonin, where oxidation of PTPs was suggested as 
the mechanism involving SERT rather than the 5-HT recep-
tors.45 In line, we observed that in female human PASMCs, 
PDGFR-β expression is increased in PAH-hPASMCs ver-
sus control hPASMCs. In control hPASMCs, expression of 
PDGFR-β was elevated by serotonin in a 5-HT1BR–dependent 
manner. This is consistent with recognized cross talk between 
platelet-derived growth factor and serotonin signaling in pul-
monary arteries.46
To test the pathophysiological significance of our find-
ings, we performed in vivo studies assessing the effects of the 
5-HT1BR antagonist, SB216641, in 2 mouse models of PH, 
the chronic hypoxic mouse, and in a serotonin-dependent 
mouse model of PH, the SERT+ mouse. Female C57BL6/J 
mice exposed to hypoxic conditions developed elevated 
RVSP, RVH, and evidence of pulmonary vascular remodeling 
parameters, which were prevented in those mice treated with 
the 5-HT1BR antagonist, SB216641. Similarly, female SERT+ 
mice developed increased RVSP and PA remodeling at 20 
weeks of age; protective effects of SB216641 treatment was 
observed. RVH remained unaffected, in line with previous 
work where our group and others have shown a dissociation 
between RVSP and RVH in the SERT+ mouse.6 We previously 
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demonstrated increased ROS expression in the SERT+ mouse 
lung25; lung ROS was reduced by the 5-HT1BR antagonist, 
suggesting that the 5-HT1BR/ROS axis is important both in 
vitro in cultured PASMCs and in vivo in the mouse lung. In 
addition, in support of the role of 5-HT1BR in human PAH, 
we observed marked 5-HT1BR staining in the endothelium and 
smooth muscle cell layers of the vasculature in human lung 
sections from PAH subjects, staining that was absent in lung 
sections from control subjects.
In conclusion, we show for the first time in hPASMCs 
from PAH patients that serotonin increases Nox1-dependent 
ROS generation and decreases Nrf-2-antioxidant systems 
through c-Src–dependent processes that contribute to oxida-
tion of proteins, DNA damage, and redox-sensitive prolifera-
tion and fibrosis of hPASMCs, processes involved in PAH. 
In line, we observed ROS-dependent protective effects of 
5-HT1BR antagonism in the SERT+ mouse model of PH. We 
identify the 5-HT1BR and both 5-HT1BR and SERT in PAH-
derived PASMCs, as being particularly important in Nox1-
derived ROS production and in serotonin-mediated vascular 
effects in PAH. Our study provides new molecular insights 
through c-Src/Nox1/ROS and Nrf-2 antioxidant mechanisms, 
whereby serotonin influences hPASMC function, which when 
upregulated may contribute to vascular injury in PAH (sum-
marized in Figure X in the online-only Data Supplement).
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Highlights
• Serotonin-induced proliferation of vascular cells, via the serotonin transporter and the 5-HT
1B
 receptor, has been associated with the develop-
ment of pulmonary arterial hypertension.
• Serotonin stimulates production of reactive oxygen species but mechanisms underlying this, and the significance of serotonin-induced reactive 
oxygen species in the development of pulmonary arterial hypertension, remain unclear. Here, we show that redox-sensitive effects of serotonin 
are associated with Nrf-2 dysregulation, contributing to oxidative stress, protein oxidation, proliferation, and extracellular matrix remodeling in 
pulmonary artery smooth muscle cells from pulmonary arterial hypertension patients.
• We demonstrate in vivo that this may contribute to the pathobiology of pulmonary hypertension.
• Therefore, inhibition of the serotonin-mediated redox system or activation of Nrf-2 could be novel therapeutic strategies in pulmonary arterial 
hypertension.
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